3 studies found for:    RENAL CANCER E7080
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Lenvatinib;   Drug: Everolimus;   Drug: Lenvatinib plus Everolimus
2 Recruiting Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Lenvatinib;   Drug: Everolimus
3 Recruiting Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Condition: Tumors
Interventions: Drug: Lenvatinib;   Drug: Pembrolizumab

Indicates status has not been verified in more than two years